- Home
- OP vs KPRX Comparison
OP vs KPRX Comparison
Compare OP & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OP
- KPRX
- Stock Information
- Founded
- OP 2021
- KPRX 1998
- Country
- OP Greece
- KPRX United States
- Employees
- OP N/A
- KPRX N/A
- Industry
- OP
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- Sector
- OP
- KPRX Health Care
- Exchange
- OP Nasdaq
- KPRX Nasdaq
- Market Cap
- OP 8.6M
- KPRX 9.2M
- IPO Year
- OP N/A
- KPRX N/A
- Fundamental
- Price
- OP $1.32
- KPRX $2.51
- Analyst Decision
- OP
- KPRX Strong Buy
- Analyst Count
- OP 0
- KPRX 1
- Target Price
- OP N/A
- KPRX $10.00
- AVG Volume (30 Days)
- OP 788.6K
- KPRX 54.5K
- Earning Date
- OP 12-19-2025
- KPRX 11-07-2025
- Dividend Yield
- OP N/A
- KPRX N/A
- EPS Growth
- OP N/A
- KPRX N/A
- EPS
- OP N/A
- KPRX N/A
- Revenue
- OP $19,435,000.00
- KPRX N/A
- Revenue This Year
- OP N/A
- KPRX N/A
- Revenue Next Year
- OP N/A
- KPRX N/A
- P/E Ratio
- OP N/A
- KPRX N/A
- Revenue Growth
- OP N/A
- KPRX N/A
- 52 Week Low
- OP $1.07
- KPRX $2.21
- 52 Week High
- OP $79.25
- KPRX $4.18
- Technical
- Relative Strength Index (RSI)
- OP 43.30
- KPRX 46.77
- Support Level
- OP $1.28
- KPRX $2.22
- Resistance Level
- OP $2.38
- KPRX $2.65
- Average True Range (ATR)
- OP 0.21
- KPRX 0.18
- MACD
- OP -0.10
- KPRX -0.01
- Stochastic Oscillator
- OP 3.62
- KPRX 53.58
About OP OceanPal Inc.
OceanPal Inc is a provider of shipping transportation services. It specializes in the ownership of vessels. Each of its vessels is owned through a separate wholly-owned subsidiary. The company includes Dry Bulk segment and Tanker segment. Majority of revenue is Dry Bulk segment.
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.